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Abstract
Background: Microglia, the resident immune cells of the brain, have been implicated in brain injury and various
neurological disorders. However, their precise roles in different pathophysiological situations remain enigmatic and
may range from detrimental to protective. Targeting the delivery of biologically active compounds to microglia
could help elucidate these roles and facilitate the therapeutic modulation of microglial functions in neurological
diseases.
Methods: Here we employ primary cell cultures and stereotaxic injections into mouse brain to investigate the cell
type specific localization of semiconductor quantum dots (QDs) in vitro and in vivo. Two potential receptors for
QDs are identified using pharmacological inhibitors and neutralizing antibodies.
Results: In mixed primary cortical cultures, QDs were selectively taken up by microglia; this uptake was decreased
by inhibitors of clathrin-dependent endocytosis, implicating the endosomal pathway as the major route of entry
for QDs into microglia. Furthermore, inhibiting mannose receptors and macrophage scavenger receptors blocked
the uptake of QDs by microglia, indicating that QD uptake occurs through microglia-specific receptor endocytosis.
When injected into the brain, QDs were taken up primarily by microglia and with high efficiency. In primary
cortical cultures, QDs conjugated to the toxin saporin depleted microglia in mixed primary cortical cultures,
protecting neurons in these cultures against amyloid beta-induced neurotoxicity.
Conclusions: These findings demonstrate that QDs can be used to specifically label and modulate microglia in
primary cortical cultures and in brain and may allow for the selective delivery of therapeutic agents to these cells.
Background
Chronic inflammation is a hallmark of many neurological
diseases [1-5]. Microglia, innate immune cells of the
CNS, become activated in response to injury and appear
to have important roles in the defense against invading
microbes and in wound repair [6]. They also phagocytose
dead cells and help clear misfolded protein aggregates,
such as those formed by amyloid beta (Ab) in Alzhei-
mer’s disease (AD) [7]. However, under certain patho-
physiological circumstances, microglia may also
contribute to neuronal toxicity. For example, factors
released from activated microglia can amplify inflamma-
tory processes that contribute to neurodegeneration [8].
To harness and modulate the activity of microglia, it
would be useful to be able to target biologically active
compounds specifically to these powerful cells.
Previously, we used viral vectors and a microglia-specific
promoter to selectively modulate gene expression in
microglia [9]. However, the usefulness of this approach is
limited by the possibility of inflammatory responses,
potential toxicity associated with viral infections, and the
inability of viral vectors to deliver a variety of chemical
compounds. Here, we demonstrate that quantum dots
(QDs) can effectively deliver biologically active molecules
to microglia in vitro and in vivo.
Semiconductor fluorescent QDs are nanometer-sized
particles with unique optical and electrical properties that
make them particularly suited for visualization and track-
ing of living cells [10-12]. They have a heavy metal core,
consisting for instance of cadmium and selenium or cad-
mium and tellurium, and an unreactive zinc sulfide shell.
Manipulation of the core size allows synthesis of a wide
array of QDs emitting at various wavelengths, visible as
different colors. Because of their composition and small
size, these nanoparticles are readily excitable by light and
display minimal photobleaching [13]. Importantly, the
* Correspondence: lgan@gladstone.ucsf.edu
1Gladstone Institute of Neurological Disease, 1650 Owens St., San Francisco
CA 94158, USA
Full list of author information is available at the end of the article
Minami et al. Journal of Neuroinflammation 2012, 9:22
http://www.jneuroinflammation.com/content/9/1/22
JOURNAL OF 
NEUROINFLAMMATION
© 2012 Minami et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
outer coating can be modified to allow for the attachment
of different bioactive molecules, offering unprecedented
possibilities to visualize and modulate molecular processes
in living cells [14,15]. QDs have been used for molecular
imaging in diverse biological systems [16]. In most cases,
surface-immobilized antibodies or peptides were used to
direct QDs to specific cellular targets. For example, QDs
conjugated to nerve growth factor (NGF) effectively acti-
vate TrkA receptors and downstream signaling cascades
that promote neuronal differentiation [17]. QDs not con-
jugated to specific antibodies or peptides appear to have
limited ability to enter most cells, especially at low concen-
trations [18]. Unconjugated QDs were found to be loca-
lized to macrophages and microglia that infiltrate
experimental gliomas [19]. However, whether QDs are
selectively taken up by microglia under normal conditions
is unknown. Here we examined the ability of QDs to enter
microglia in primary cultures and mouse brains and the
underlying cellular mechanisms.
Methods
Quantification of QD uptake
Water-soluble ZnS capped CdSe streptavidin coated quan-
tum dots (QDs) with emission at 655 nm were purchased
from Invitrogen. QD solution was added to mixed cortical
cultures at 0.5 nM for 1-48 h. The uptake of QDs was
visualized under epifluorescence or confocal microscopy
with an XF02-2 filter from Omega Optical that allows
simultaneous multi-color viewing (Omega Optical, Brattle-
boro, VT). For visualization of QD655 uptake in mouse
brain, confocal images were taken with a Nipkow spinning
disk confocal microscope. GFP signal was imaged with a
488 nm laser and 515 nm bandpass, and QDs were imaged
with a 405 nm and a 700 nm bandpass emission filter.
Images were acquired in 0.5 nm step sizes in the z dimen-
sion. The amounts of QDs taken up by the cells were
quantified with MetaMorph (Molecular Devices Corpora-
tion, Sunnyvale, CA). To investigate the mechanisms by
which microglia take up QDs, cortical cultures were pre-
treated with chlorpromazine (CPZ) (6-20 μM), cytochala-
sin B (CTB) (4-8 μM), bafilomycin (BAF) (25-50 nM),
mannan (1-2 mg/ml), polyinosinic acid (100-200 μg/ml),
or blocking antibodies (anti-mannose receptor, anti-
macrophage scavenger receptor, 2 μM) for 2 h before add-
ing QD solutions, followed by 24 h incubation before
analyses.
Primary mixed culture and microglial culture
Cortices were isolated from Sprague-Dawley rat pups
(Charles River Laboratories, Wilmington, MA) on post-
natal day 0 or 1. To establish mixed cortical cultures,
cells were plated at 160,000 cells/ml in plating medium
containing Dulbecco’s modified Eagle’s medium
(DMEM), 10% fetal bovine serum, 0.5 mM glutamax, and
100 U/ml penicillin and 100 μg/ml streptomycin for 7
days, as described [9].
Primary microglial cultures were prepared from 1-day-
old mice as described [20]. Cortices were dissociated by
mincing and incubation in papain and DNase. After cen-
trifugation for 5 min at 500 × g, the cells were resus-
pended by trituration with a fire-polished Pasteur pipette,
plated on 6-well plates (Falcon/BD Biosciences) at a den-
sity of 6.4 × 105 cells/well, and maintained in a 37°C, 5%
CO2 incubator. The culture medium consisted of Eagle’s
minimal essential medium (MEM, Gibco) supplemented
with 10% endotoxin-free fetal bovine serum (HyClone),
2 mM glutamine, and streptomycin. After 2 weeks in
vitro, microglia were harvested by mildly shaking the cul-
tures and collecting the floating cells. These cells were
re-plated at a density of 5 × 105 cells/well in 24-well
plates. The microglial cultures were used for experiments
2 days after re-plating. Each culture well was visually
inspected by phase contrast microscopy before use, and
wells containing contaminating astrocytes or greater than
30% activated microglia were excluded. Microglia with
enlarged soma and less than two branching processes
were considered activated. Experiments were performed
in MEM, in which all drug stocks were diluted. All tissue
culture supplies were purchased from Invitrogen (Carls-
bad, CA) unless stated otherwise.
Cytokine assay
Microglial cultures were placed in 300 μl MEM alone
(ctrl) or with QDs (0.5 nM) for 6 h, after which the
Qdots were washed out, and the microglia were placed
in fresh MEM or lipopolysaccharide (LPS) (50 ng/ml)
for 20-22 h. Medium samples were taken and treated
with complete protease inhibitor and stored in -70°C.
Medium (50 μl) was evaluated with a Beadlyte mouse
14-plex cytokine detection system (Millipore), according
to the manufacturer’s instructions. This immunoassay
method employs 14 cytokine-specific antibodies tagged
with fluorescent beads. Assays were performed in dupli-
cate, and the fluorescent signal corresponding to each
cytokine was measured with a BioPlex 200 system
(Biorad). Values were normalized to the protein content
of each well as determined by the bicinchoninic assay
[21].
Immunocytochemistry
Cultures were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 15-30 min at room temperature.
After permeabilization in PBS with 0.1% Triton for
10 min, cells were placed in blocking buffer (PBS with
10% FBS and 0.01% Triton) for 30 min. To label microglia,
primary antibodies to Iba-1 (1:250, Wako Pure Chemical
Industries, Osaka, Japan) or anti-CD11b (1:200, Chemicon,
Temecula, CA) were applied in blocking buffer overnight
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at 4°C and visualized with anti-rabbit (Iba-1) or anti-rat
(CD11b) conjugated with FITC (Vector Laboratories, Bur-
lingame, CA). To identify astroglia or neurons, GFAP
(1:1000; DAKO, Carpinteria, CA) or MAP2 (1:500; Chemi-
con, Temecula, CA) antibodies, respectively, were applied
in blocking buffer for 2 h at room temperature or over-
night at 4°C and visualized with anti-rabbit (GFAP) or
anti-mouse (MAP2) conjugated with FITC (Vector
Laboratories).
Stereotaxic injection of QDs into the brain
The QD solution (3 μl at 100 nM) was stereotaxically
injected into the hippocampus of CX3CR+/- mice, which
express green fluorescent protein (GFP) in microglia, at
the following coordinates relative to bregma: anterior pos-
terior: -2.1, medial lateral: ± 1.7, dorsal ventral: -2.0. The
brains were perfused and fixed in 4% paraformaldehyde
2-28 days later.
Quantum dots conjugation with saporin
The avidin-biotin affinity interaction was used to con-
jugate saporin to QDs. Briefly, 2 μl of QDs (1 μM)
were mixed with 2 μl of biotinlyated saporin (56 μM),
and 76 μl of PBS was added. The solutions were incu-
bated at room temperature with continuous shaking
for at least 2 h before they were used for analysis or
treatment. X-ray photoelectron spectroscopy (XPS)
analysis was performed to determine the chemical
composition of saporin-conjugated QDs. Unconjugated
and saporin-conjugated QDs were adsorbed on a sili-
con surface for ease with XPS analysis. An x-ray photo-
electron spectrometer with a monochromatic Al-Ka-X-
ray small spot source (1486.6 eV) and multichannel
detector was used for this analysis. A concentric hemi-
spherical analyzer was operated in constant analyzer
transmission mode to measure the binding energies of
emitted photoelectrons. The binding energy scale was
calibrated by the Au4f7/2 peak at 83.9 eV, and the line-
arity was verified by the Cu3p1/2 and Cu2p3/2 peaks at
76.5 and 932.5 eV, respectively. Survey spectra were
collected from 0 to 1100 eV with pass energy of 160
eV, and high-resolution spectra were collected for the
C1s peak with pass energy of 10 eV. All spectra were
referenced by setting the C1s peak to 285.2 eV to com-
pensate for residual charging effects. Data for percent
atomic composition and atomic ratios were calculated
using analysis software. For peak fit analysis, a convolu-
tion of Gaussian components was assumed for all peak
shapes. High-resolution C1s scans were taken to
further support the presence of saporin on the QDs.
The major hydrocarbon peak (C-C) is at 285.2 eV. The
binding energy at 286.8 eV is assigned to amines
(CH2N) and the binding energy at 288.0 eV is assigned
to amide functional groups (O = C-N).
Ab treatment and cell death quantification
Ab1-42 peptides lyophilized in hydroxyfluroisopropanol
(HFIP) were purchased from rPeptide (Athens, GA).
Lyophilized Ab powder was reconstituted immediately
before being diluted in Neurobasal A/N2 medium to
10-20 μM. Loss of neurons in mixed cultures was mea-
sured as described [9]. MAP2-positive neurons were
counted in 15-40 random fields under a fluorescence
microscope (400 × magnification).
Results
Selective uptake of QDs by microglia in primary cortical
cultures
The passive uptake of QDs was investigated in primary
cultures derived from neonatal rat cortices, which con-
tain three main cell types: MAP2-positive neurons,
GFAP-positive astrocytes, and CD11b-positive microglia
[9]. Commercial QDs (QD-streptavidin, Invitrogen; emit-
ting at 655 nm) were applied to the mixed culture system
at different concentrations and visualized 1-48 h later.
QDs were selectively internalized by microglia labeled
with antibodies against CD11b or Iba-1 (Figure 1A). At
QD concentrations of 0.5 nM, 38.9 ± 4.5% of Iba-1-posi-
tive microglia contained QDs after 18 h incubation. In
contrast, no QDs were observed in GFAP-positive astro-
glia (Figure 1B) or MAP-2 positive neurons (Figure 1C).
At 4 nM concentration, microglia started to internalize
QDs within 1 h (Figure 1D), followed by a gradual intra-
cellular accumulation of QDs during the next 48 h (Fig-
ure 1D). These results suggest that QDs are stable and
not sensitive to intracellular degradation. Importantly,
after 72 h incubation, QDs did not colocalize with
Annexin V/Sytox green, which labels apopotic/necrotic
cells (Figure 1E), suggesting that uptake and retention of
QDs does not induce toxicity in culture.
To determine whether the selective uptake of QDs by
microglia is influenced by surface chemistry, we used QDs
with an amine-derivatized polyethylene glycol (PEG) outer
coating that reacts directly with amine-reactive groups
(QD655-PEG), QDs with a carboxyl coating (QD655-car-
boxy), or QDs with a PEG coating conjugated to streptavi-
din (QD655-PEG-Strep). QD655-PEG, QD655-PEG-Strep,
and QD655-Carboxy were all selectively taken up by
microglia in mixed cortical cultures (Figure 1F).
We next tested whether the size of QDs affected their
ability to enter microglia. QDs of different sizes emit at
different wavelengths of the visible spectrum; therefore,
QDs of different sizes can be distinguished by their color.
We compared QDs emitting at 525, 605, 655, or 705 nm,
and found that QD655 was the most efficient at entering
microglia (Figure 2A-B). However, despite their different
efficiencies, all QDs tested were selectively taken up by
microglia in mixed cortical cultures, regardless of their
emission wavelengths.
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Figure 1 Selective uptake of QDs by microglia in mixed primary cortical cultures. A. In mixed primary cortical cultures from rats, QDs (red)
were internalized primarily by microglia labeled with anti-CD11b (green) or anti-Iba-1 (green) antibodies. Nuclei were labeled with DAPI (blue).
Scale bar, 50 μm. Inset, higher magnification of a QD-containing microglia cell labeled with Iba-1 antibody. B, C. QDs (red) were not found in
astrocytes labeled with anti-GFAP (green, B) or in neurons labeled with anti-MAP2 (green, C). Scale bar, 50 μm. D. Fluorescence intensity of QDs
in microglia increased with time of incubation. n = 30-100 cells from 5-6 independent images measured with Metamorph analyses. * P < 0.05
(24 h vs. 48 h), *** P < 0.001 (3 h vs. 8 h, and 8 h vs. 24 h); one-way ANOVA with Tukey-Kramer posthoc analyses. Error bars represent SEM. E.
QDs (red) were not detected in apoptotic or necrotic cells labeled with Annexin V/Sytox green (green). Scale bar, 50 μm. F. Microglial
internalization of QD655 conjugated with polyethylene glycol (QD655-PEG), PEG-streptavidin (QD655-PEG-Strep), or -COO- (QD655-Carboxyl) in
mixed cortical cultures. Red: QDs; green: Iba-1-positive microglia. Scale bar, 50 μm.
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QD uptake does not affect release of cytokines in primary
microglia
To determine if uptake of QDs per se alters microglial
function, we measured the release of inflammatory cyto-
kines from primary microglia treated with QDs or with
medium alone. QD treatment of primary microglia did not
alter their release of tumor necrosis factor a (TNFa), KC,
RANTES, MIP-1a, MIP-1b, or IP-10 (Table 1). Treatment
with QDs also did not change the microglial release of
cytokines in response to lipopolysaccharide (Table 1).
The uptake of QDs by microglia depends on clathrin-
mediated endocytosis
We next investigated the mechanism underlying the entry
of QDs into microglia. Because the diameter of QDs
ranges from 10-100 nm, we hypothesized that QDs tra-
verse the cell membrane via endocytosis rather than pha-
gocytosis [22]. Since pH sensitivity is considered a good
indicator of entry by endocytosis, we examined if the
uptake of QDs by microglia depends on pH. The specific
inhibitor of endosomal proton-ATP pumps bafilomycin
(BAF) elevates the pH in endocytic compartments to neu-
trality. The entry of QDs into microglia was blocked by
BAF in a dose-dependent manner (Figure 3A-B), suggest-
ing that this process depends on the acidification of
endosomes.
To further dissect the molecular mechanisms underly-
ing QD endocytosis, we investigated if the entry of QDs
depends specifically on clathrin-mediated endocytosis, a
well-studied mode of endocytosis that is crucial for
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Figure 2 Size of QDs affects their uptake by microglia. A. Internalization of QDs of different sizes by microglia. Blue: DAPI. B. Size-dependent
internalization of QDs by microglia was quantified by fluorescence intensity with Metamorph analyses. n = 23-39 cells from 5-6 independent
images. ***, P < 0.001 by Tukey-Kramer posthoc test. Bars represent mean ± SEM. Scale bar, 20 μm.
Table 1 Microglial release of cytokines
TNFa IL-1a IL-1b IL-6 KC RANTES G-CSF MCP-1 MIP-1a MIP-1b IP-10
Ctrl 0.9 ± 0.5 ND ND 2.3 ± 1.7 1.4 ± 0.8 2.3 ± 1.7 ND ND 2.4 ± .9 3.8 ± 1.5 54.6 ± 35.3
(n = 3)
Qdots 0.3 ± 0.1 ND ND ND 0.5 ± 0.1 1.2 ± 0.01 ND ND 1.5 ± 1.0 3.2 ± 3.0 17.6 ± 9.8
(n = 2)
LPS 226.5 ± 9.4 6.3 ±
3.2
1.7 ±
0.8
471.9 ±
34.6
345.5 ±
21.0
391.8 ±
19.0
53.9 ±
9.3
12.1 ± 7.2 592.7 ± 76.3 500.0 ± 23 189.8 ±
14.2
(n = 3)
LPS+ 217.1 ±
47.4
9.6 ±
6.9
2.6 ±
2.1
533 ±
197.5
363.5 ±
89.4
394.5 ±
84.2
49.4 ±
5.3
20.7 ±
17.9
637.3 ±
263.5
519.2 ±
169.0
196.0 ±
53.9
Qdots (n =
2)
Cytokines (pg/ml) released by primary microglia treated with vehicle, QD, LPS, or LPS + QD (mean ± SEM). n, number of wells per condition. ND not detected, G-
CSF granulocyte colony-stimulating factor, IP-10 10 kDa interferon-gamma-induced protein, KC, keratinocyte chemoattractant, MCP-1 monocyte chemotactic
protein-1, MIP-1a macrophage inflammatory protein 1 alpha, MIP-1b macrophage inflammatory protein 1 beta, RANTES, regulated upon activation. The following
cytokines were undetectable in all conditions: VEGF, IFNg, and IL-10
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many physiological functions, including the rapid clear-
ance and down regulation of activated signaling recep-
tors and the efficient recycling of synaptic vesicle
membrane proteins after neurotransmission. Cells were
treated with CPZ, a cationic amphiphilic drug that
prevents the recycling of clathrin and thus prevents
endocytosis by clathrin-dependent mechanisms [23].
Treatment with CPZ at 10-20 μM significantly inhibited
the entry of QDs into microglia (Figure 3C-D). Clathrin-
mediated entry can be also be inhibited by CTB, which
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Figure 3 The uptake of QDs by microglia depends on clathrin-mediated endocytosis. The internalization of QDs by microglia was blocked
dose-dependently by bafilomycin (BAF) (A, B), chlorpromazine (CPZ) (C, D), or cytochalasin B (CTB) (E, F). n = 18-48 cells per condition. ** P <
0.01, *** P < 0.001, vs. Vehicle (0.1% ethanol) or non-treated (NT) by Tukey-Kramer posthoc test. Bars represent mean ± SEM. Scale bar, 20 μm.
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induces depolymerization of actin filaments [24]. F-actin
dynamics have been shown to be necessary for various
stages of clathrin-coated vesicle formation, including
coated pit formation, constriction, and internalization
[25]. Treatment with CTB induced a dose-dependent
decrease in QD entry into microglia (Figure 3E-F). Both
CPZ and CTB inhibit transferrin (a specific maker for
clathrin-mediated endocytosis) at the concentrations
used in the current study [26], strongly supporting the
notion that QDs enter microglia through clathrin-
mediated endocytosis.
The uptake of QDs by microglia occurs through mannose
and macrophage scavenger receptors
To determine if microglia-specific receptors, such as
macrophage scavenger receptor 1 (MSR-1) [27-29] and
mannose receptor [30], mediate the uptake of QDs, we
treated primary mixed cortical cultures with inhibitors
against these receptors and measured QD uptake by
microglia. Mannan, an inhibitor of mannose receptor,
dose-dependently decreased microglial uptake of QDs
(Figure 4A). Polyinosinic acid (PIA), an inhibitor of macro-
phage scavenger receptor, also decreased microglial uptake
of QDs (Figure 4B). Treatment with anti-mannose recep-
tor (MR) or anti-macrophage scavenger receptor (MSR)
antibodies also blocked microglial uptake of QDs (Figure
4C). These results implicate microglia-specific receptors in
the selective uptake of QDs by microglia.
Selective uptake of QDs by microglia in mouse brains
We next injected QDs (3 μl of 100 nM) into the hippocam-
pus of CX3CR+/- mice, which express green fluorescent
protein (GFP) in microglia. QDs spread throughout most
of the hippocampus (Figure 5A), Consistent with the selec-
tive targeting of QDs to microglia in cortical primary cul-
tures, QDs were also predominantly localized in microglia
in the brain (Figure 5C-D). Internalized QDs in microglia
were further confirmed with Z-stack images (Figure 5E)
and a 3D reconstruction of the confocal images (Additional
file 1). In contrast, very little uptake of QDs was observed
by GFAP-positive astroglia (Figure 5F) or MAP-2-positive
neurons (Figure 5G). On some occasions, though, weak
fluorescent signals were detected in the neurons of the
dentate gyrus, suggesting limited neuronal uptake of QDs
at high concentrations in vivo. Our results indicate that in
the mouse brains, QDs target microglia preferentially and
with high efficiency. Interestingly, the strong fluorescent
signal remained stable for at least 1 month after the injec-
tion (Figure 6), supporting the feasibility of following the
QDs long term.
QD-saporin-mediated depletion of microglia decreases
Ab-induced neuronal loss
We next investigated if QDs could be used to deliver
biologically active compounds selectively to microglia.
Exposure of mixed cortical cultures to pathogenic Ab
aggregates, which are widely thought to cause AD,
results in the degeneration of neurons. Notably, this
neurotoxicity is at least partially dependent on the pre-
sence of microglia [31,32]. We therefore wanted to
determine if the Ab-induced neurotoxicity in such cul-
tures could be suppressed by delivering a cytotoxin spe-
cifically to microglia through QDs. For this purpose, the
cytotoxin saporin, which belongs to a family of single-
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Figure 4 Microglial uptake of QDs occurs through mannose receptors and macrophage scavenger receptors. A. The internalization of
QDs by microglia in rat primary mixed cortical cultures was quantified by fluorescence intensity with Metamorph software. Microglial uptake of
QDs was blocked in a dose-dependent manner by mannan, an inhibitor of mannose receptors (A) and by polyinosinic acid (PIA), an inhibitor of
scavenger receptors (B). n = 120-200 cells from at least eight separate images. Experiments were repeated three times. C. Antibodies against
mannose receptor (MR) or macrophage scavenger receptor (MSR) were applied to rat primary mixed cortical cultures at a 2 μM concentration
for 2 h before incubation with QDs. Microglial uptake of QDs was blocked by antibodies against MR and MSR. n = 105-120 cells from at least
eight separate images. Experiments were repeated twice. ***P < 0.001, **P < 0.01, *P < 0.05 vs. control-treated, one-way ANOVA with Tukey-
Kramer posthoc analyses. Bars represent mean ± SEM.
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chain ribosome inactivating proteins (RIPs), was biotiny-
lated for coupling with QD-streptavidin. Saporin conju-
gated to an antibody against Mac1 (CD11b) has been
used to selectively kill microglia in hippocampal slice
cultures and in rat brain [33,34]. Here, we tested
whether conjugation of saporin with QDs could result
in similar microglia-specific cell loss.
To confirm the conjugation of saporin with QDs, XPS
was used to compare the chemical composition of
unconjugated and saporin-conjugated QDs adsorbed on
a silicon surface. While negligible carbon was present on
the silicon surface due to impurities, the carbon composi-
tion increased for the silicon surface adsorbed with QDs.
There was a further increase in carbon for surface
adsorbed with saporin-conjugated QDs, consistent with
the presence of streptavidin and saporin, which are com-
posed predominantly of carbon (Figure 7A, Table 2A).
This increase was associated with a decrease in oxygen
composition on the surfaces (Figure 7A, Table 2A).
Moreover, there was a decrease in the elements present
in QDs, namely Se, S, Cd and Zn after conjugation with
saporin, further suggesting successful conjugation.
High-resolution C1s scans were taken to further support
the presence of saporin on the QDs (Figure 5B, Table 2B).
The major hydrocarbon peak (C-H) was at 285.2 eV. A
binding energy at 286.8 eV is assigned to amines (CH2N),
and a binding energy at 288.0 eV is assigned to amide
functional groups (O = C-N). For the silicon surface, there
was only one peak at 285.2 eV. For QDs, apart from the
hydrocarbon peak at 285.2 eV, peaks for amine (at 286.8
eV) and amide (at 288 eV) were also present. After saporin
conjugation, the intensities of the amine and amide peaks
increased, as shown in the deconvolution of high-resolu-
tion C1s spectra into individual peaks. The decreased
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Figure 5 QDs are selectively taken up by microglia in vivo. A-D. QDs were stereotaxically injected into the hippocampus of CX3CR+/- mice,
which express GFP in microglia. A. Representative photomicrographs showing the distribution of QDs in the hippocampus. B. GFP-labeled
microglia in the hippocampus. C. Merge of (A) and (B) shows that the majority of QDs were localized in microglia. Scale bar, 200 μm. D. Higher
magnification image of the boxed area in (C). Scale bar, 20 μm. E. Representative confocal image through a single plane of quantum dots (red)
internalized by microglia (green) in the hippocampus of CX3CR+/- mice. Blue: DAPI. Scale bar, 20 μm. F, G. QDs (red) were not taken up by
astrocytes labeled with anti-GFAP (green, F) or neurons labeled with anti-MAP2 (green, G) after they were injected into the hippocampus of
C57Bl/6 wildtype mice. Scale bar, 20 μm.
Minami et al. Journal of Neuroinflammation 2012, 9:22
http://www.jneuroinflammation.com/content/9/1/22
Page 8 of 13
contribution of the hydrocarbon peak at 285.2 eV and the
subsequent increase in amide and amine peaks at other
binding energies reflect the successful conjugation of the
QD surface with saporin.
We then applied QDs conjugated with saporin to pri-
mary cultures for 2 days and quantified microglia after the
treatment by Iba-1 expression. Application of QD-Sap
caused a marked reduction of microglia labeled with an
antibody against Iba-1, without affecting the number or
morphology of neurons or astroglia (Figure 8A and 8B).
Treatment with unconjugated QDs or saporin alone did
not significantly affect the number of microglia compared
with untreated control (data not shown).
Next, we tested the effects of QD-Sap-induced micro-
glial ablation on Ab toxicity in mixed cortical cultures.
Depletion of microglia with QD-Sap significantly increased
the number of MAP2-positive neurons that survived Ab1-
42 treatment (Figure 8C). Application of QDs or saporin
alone had no effects. Thus, neurons could be preserved in
this neurodegenerative disease model through the selective
targeting of microglia with modified QDs.
Discussion
Our study shows that QDs are preferentially taken up by
microglia in mixed cortical cultures and in brain. We
further showed that the major cellular uptake pathway
$ %
GD\V GD\V
Figure 6 Long-term expression of QDs. A, B. QDs are observed 7 days (A) and 28 days (B) after injection into the hippocampus of adult
C57BL/6 mice. Scale bar, 200 μm.
$ %
Figure 7 Conjugation of QDs with saporin by streptavidin-biotin binding. A. Comparison of carbon composition of QDs and QD-saporin
conjugates measured by X-ray photoelectron spectroscopy. B. High-resolution C1 scans confirmed the presence of saporin on the surface of
QDs.
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of QDs in microglia is clathrin-mediated endocytosis
involving the microglia-specific receptors MSR-1 and
mannose receptor. In primary mixed cortical cultures,
QDs effectively delivered the cytotoxin saporin selec-
tively to microglia. Depletion of microglia with QD-Sap
resulted in protection against microglia-mediated Ab
toxicity.
Our finding that QDs are selectively taken up by
microglia is consistent with previous observations that
QDs were localized to macrophages and microglia that
infiltrate experimental gliomas [19]. However, in con-
trast to the previous study, which suggested that QDs
were phagocytosed by macrophages and microglia, our
data indicate that QDs enter microglia via receptor
binding and clathrin-mediated endocytosis. In eukar-
yotes, macromolecules enter the cell in membrane-
bound vesicles either via ‘phagocytosis’ (the uptake of
particles larger than 0.5 μm in diameter) or ‘pinocytosis’
(the uptake of fluid and solutes) [22]. Phagocytosis
occurs by an actin-dependent mechanism and is usually
independent of pH gradient and clathrin, whereas pino-
cytosis occurs by at least four basic mechanisms: macro-
pinocytosis, clathrin-mediated endocytosis, calveolae-
mediated endocytosis, and clathrin- and calveolae-inde-
pendent endocytosis [22]. Interestingly, the uptake of
soluble Ab by microglia was found to be mediated
through a nonsaturable, fluid phase macropinocytic
mechanism that is distinct from phagocytosis and recep-
tor-mediated endocytosis [35]. The size of QDs, which
range from 10-100 nm in diameter, makes it unlikely
that QDs enter microglia via phagocytosis. Indeed, the
blockade of QD entry by balifomycin, chlorpromazine,
and cytochalasin B provide strong evidence that QDs
are taken up by microglia via clathrin-mediated endocy-
tosis. Clathrin-mediated endocytosis occurs in all cell
types. However, blocking the MSR-1 or mannose recep-
tor with specific inhibitors or antibodies prevented the
uptake of QDs, indicating that the selective targeting of
QDs to microglia requires their binding to microglia-
specific receptors. We cannot exclude that other micro-
glial receptors such as Fc-receptors, complement recep-
tors, and Toll-like receptors might also mediate the
endocytosis of QDs by microglia. Additional studies are
needed to fully characterize the potential binding sites
of QDs on the microglial surface.
The unique optical properties of quantum dots, such as
high quantum yields, large molar extinction coefficients,
size-dependent tunable emission and high photostability,
make them appealing as fluorescent probes for biological
imaging. On the other hand, because of their size range,
QDs are also very suitable for manipulations at the mole-
cular level, offering new approaches for the delivery of
potent bioactive agents. Microglia may have roles in the
pathogenesis of various CNS diseases, including multiple
sclerosis, Alzheimer’s disease, Parkinson’s disease, and
amyotropic lateral sclerosis [36-39]. Our finding that cer-
tain sizes of QDs selectively target microglia provides a
novel platform to probe and modulate biological pro-
cesses in microglia and may lay the foundation for the
development of QD-based reagents that can modulate
specific signaling pathways in microglia.
In contemplating the therapeutic potential of QDs, an
important caveat is their biocompatibility and toxicity
[18,40]. The use of PEG on the surface of the QDs sig-
nificantly improved their biocompatibility and mini-
mized their toxicity [41-43]. A gene profiling study
showed that application of high-dose QDs only induced
changes in a small number of genes associated with the
transport machinery, supporting the feasibility of long-
term usage of QDs in biological systems [41]. The cur-
rent study provides evidence that targeting of microglia
with QDs is unlikely to result in toxicity through
increased cytokine release, even in the presence of LPS-
stimulated microglial activation. Indeed, our data sug-
gest that the toxicity of QDs is limited, at least in the
short term. However, evidence suggests that QDs may
activate autophagy, implicating an important role in the
regulation of normal cell processes [44-47]. The size-
dependent induction of autophagy by QDs could result
in the initiation of a cell death cascade [48]. Alterna-
tively, the induction of autophagy during inflammation
may protect against the harmful effects of microglial
activation. Further investigation will be required to
establish the long-term effects of the material, especially
the heavy-metal component, in biological systems. If
Table 2 Saporin conjugation of QDs characterized by X-
ray photoelectron spectroscopy
Binding Energy (eV) Atomic %
A. Silicon QDs QD-Sap
Se3d3/2 57 0 0.47 0.36
Si2s 151 50.62 0 0
S2p1/2 165 0 1.8 1.25
C1s 285 9.09 78.08 80.27
N1s 398 0 1.24 0.74
Cd3d5/2 405
O1s 523 40.29 17.94 17.02
Zn2p3/2 1022 0 0.47 0.36
B. Silicon QDs QD-Sap
285.2eV C-H (hydrocarbon) 100 65 54
286.8eV CH2N (amine) 0 27 32
288.0eV O = C-N (amide) 0 8 14
A. Surface elemental composition calculated by XPS survey scans. B. High-
resolution C1s peak deconvoluted into its components and indicating the
composition of individual peaks on each surface
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their safety profile continues to improve, QDs may
emerge as a novel approach for the selective delivery of
therapeutic agents to microglia in diverse CNS diseases.
Conclusions
In conclusion, our study demonstrates that QDs can be
used to specifically label and modulate microglia in pri-
mary cortical cultures and in the brain. This specificity
is in part due to the selective uptake by macrophage
scavenger receptors and mannose receptors present on
the surface of microglia. These findings may allow for
the selective imaging and delivery of therapeutic agents
to microglia in a wide range of neurological disease
models and, ultimately, perhaps also in the correspond-
ing human conditions.
Additional material
Additional file 1: Quantum dots are internalized by microglia. CX3CR
+/- mice, which express GFP in microglia, were injected with QD655 into
the hippocampus. QD were imaged 48 h after injection, and z-stack
confocal images were compiled into a 3D movie. Red: QDs, Green:
microglia.
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Figure 8 QD-saporin-mediated depletion of microglia decreases neuronal loss in mixed cortical cultures exposed to Ab. A.
Representative photomicrographs of microglial cells in mixed cortical cultures treated with QDs or QD-saporin (QD-Sap) conjugates. Microglial
cells were labeled with anti-Iba-1 (green) and nuclei were labeled with DAPI (blue). B. Quantification of Iba-1-positive cells in mixed cultures
treated with unconjugated saporin (Sap), QDs, or QD-saporin conjugates (QD-Sap). C. Quantification of MAP2-positive neurons in mixed cultures
treated with Ab1-42 after pretreatment with medium alone, QDs, or QD-Sap. n = 5 wells from three independent experiments. *P < 0.05, **P <
0.01, one-way ANOVA with Tukey-Kramer posthoc analyses. Scale bar, 100 μm.
Minami et al. Journal of Neuroinflammation 2012, 9:22
http://www.jneuroinflammation.com/content/9/1/22
Page 11 of 13
macrophage scavenger receptor 1; NGF: nerve growth factor; PEG:
polyethylene glycol; QD: quantum dot; RANTES: regulated upon activation:
normal T-cell expressed: and secreted (also known as chemokine (C-C motif)
ligand 5 (CCL5)); RIP: ribosome inactivating protein; VEGF: vascular
endothelial growth factor; XPS: X-ray photoelectron spectroscopy.
Acknowledgements
We thank Gary Howard and Stephen Ordway for editorial assistance and
Vivian Shen for technical assistance. This work was supported in part by a
grant from the NIH (AG030207-A2) and a gift from the S. D. Bechtel, Jr.
Foundation. The J. David Gladstone Institutes received support from a
National Center for Research Resources Grant RR18928-01.
Author details
1Gladstone Institute of Neurological Disease, 1650 Owens St., San Francisco
CA 94158, USA. 2Department of Neurology, University of California, San
Francisco, 505 Parnassus Ave., San Francisco CA, 94143, USA. 3Department of
Bioengineering and Therapeutic Sciences, University of California, San
Francisco, 513 Parnassus Ave., San Francisco CA 94143, USA. 4Department of
Chemistry, University of Pittsburgh, 219 Parkman Ave., Pittsburgh PA 15260,
USA. 5Department of Mechanical Engineering, Colorado State University, Fort
Collins CO 80523, USA.
Authors’ contributions
SSM, BS, TK, KP, MEW, and YZ conducted experiments. LG, LM, and TD
conceived the project. LG, BS, MP and SSM designed experiments. LG and
SSM wrote the manuscript. All authors have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 October 2011 Accepted: 24 January 2012
Published: 24 January 2012
References
1. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG: Does
neuroinflammation fan the flame in neurodegenerative diseases? Mol
Neurodegener 2009, 4:47.
2. Colton CA: Heterogeneity of microglial activation in the innate immune
response in the brain. J Neuroimmune Pharmacol 2009, 4:399-418.
3. Akiyama H, McGeer PL: Brain microglia constitutively express β-2
integrins. J Neuroimmunol 1990, 30:81-93.
4. Town T, Nikolic V, Tan J: The microglial “activation” continuum: from
innate to adaptive responses. J Neuroinflammation 2005, 2:24.
5. Lucin KM, Wyss-Coray T: Immune activation in brain aging and
neurodegeneration: too much or too little? Neuron 2009, 64:110-122.
6. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering
the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
7. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T,
Hoenow K, Hu K, Johnson-Wood K, et al: Epitope and isotype specificities
of antibodies to β-amyloid peptide for protection against Alzheimer’s
disease-like neuropathology. Proc Natl Acad Sci USA 2003, 100:2023-2028.
8. Wyss-Coray T, Mucke L: Inflammation in neurodegenerative disease–a
double-edged sword. Neuron 2002, 35:419-432.
9. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L:
SIRT1 Protects against Microglia-dependent Amyloid-{beta} Toxicity
through Inhibiting NF-{kappa}B Signaling. J Biol Chem 2005,
280:40364-40374.
10. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Sundaresan G,
Wu AM, Gambhir SS, Weiss S: Quantum dots for live cells, in vivo
imaging, and diagnostics. Science 2005, 307:538-544.
11. Du W, Wang Y, Luo Q, Liu BF: Optical molecular imaging for systems
biology: from molecule to organism. Anal Bioanal Chem 2006,
386:444-457.
12. Alivisatos AP, Gu W, Larabell C: Quantum dots as cellular probes. Annu Rev
Biomed Eng 2005, 7:55-76.
13. Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP: Semiconductor
nanocrystals as fluorescent biological labels. Science 1998,
281:2013-2016.
14. Gao X, Cui Y, Levenson RM, Chung LW, Nie S: In vivo cancer targeting and
imaging with semiconductor quantum dots. Nat Biotechnol 2004,
22:969-976.
15. Azzazy HM, Mansour MM, Kazmierczak SC: From diagnostics to therapy:
prospects of quantum dots. Clin Biochem 2007, 40:917-927.
16. Jaiswal JK, Simon SM: Potentials and pitfalls of fluorescent quantum dots
for biological imaging. Trends Cell Biol 2004, 14:497-504.
17. Vu TQ, Maddipati R, Blute TA, Nehilla BJ, Nusblat L, Desai TA: Peptide-
conjugated quantum dots activate neuronal receptors and initiate
downstream signaling of neurite growth. Nano Lett 2005, 5:603-607.
18. Delehanty JB, Mattoussi H, Medintz IL: Delivering quantum dots into cells:
strategies, progress and remaining issues. Anal Bioanal Chem 2009,
393:1091-1105.
19. Jackson H, Muhammad O, Daneshvar H, Nelms J, Popescu A,
Vogelbaum MA, Bruchez M, Toms SA: Quantum dots are phagocytized by
macrophages and colocalize with experimental gliomas. Neurosurgery
2007, 60:524-529, discussion 529-530.
20. Kauppinen TM, Swanson RA: Poly(ADP-ribose) polymerase-1 promotes
microglial activation, proliferation, and matrix metalloproteinase-9-
mediated neuron death. J Immunol 2005, 174:2288-2296.
21. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD,
Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein
using bicinchoninic acid. Anal Biochem 1985, 150:76-85.
22. Doherty GJ, McMahon HT: Mechanisms of endocytosis. Annu Rev Biochem
2009, 78:857-902.
23. Wang LH, Rothberg KG, Anderson RG: Mis-assembly of clathrin lattices on
endosomes reveals a regulatory switch for coated pit formation. J Cell
Biol 1993, 123:1107-1117.
24. Sampath P, Pollard TD: Effects of cytochalasin, phalloidin, and pH on the
elongation of actin filaments. Biochemistry 1991, 30:1973-1980.
25. Yarar D, Waterman-Storer CM, Schmid SL: A dynamic actin cytoskeleton
functions at multiple stages of clathrin-mediated endocytosis. Mol Biol
Cell 2005, 16:964-975.
26. Hussain KM, Leong KL, Ng MM, Chu JJ: The essential role of clathrin-
mediated endocytosis in the infectious entry of human enterovirus 71. J
Biol Chem 2011, 286:309-321.
27. Krieger M, Herz J: Structures and functions of multiligand lipoprotein
receptors: macrophage scavenger receptors and LDL receptor-related
protein (LRP). Annu Rev Biochem 1994, 63:601-637.
28. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T: Inflammation
in Alzheimer’s disease: amyloid-beta oligomers trigger innate immunity
defence via pattern recognition receptors. Prog Neurobiol 2009,
87:181-194.
29. Yang CN, Shiao YJ, Shie FS, Guo BS, Chen PH, Cho CY, Chen YJ, Huang FL,
Tsay HJ: Mechanism mediating oligomeric Abeta clearance by naive
primary microglia. Neurobiol Dis 2011, 42:221-230.
30. Marzolo MP, von Bernhardi R, Inestrosa NC: Mannose receptor is present
in a functional state in rat microglial cells. J Neurosci Res 1999, 58:387-395.
31. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F:
Proinflammatory profile of cytokine production by human monocytes
and murine microglia stimulated with beta-amyloid[25-35]. J
Neuroimmunol 1999, 93:45-52.
32. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD:
Scavenger receptor-mediated adhesion of microglia to beta-amyloid
fibrils. Nature 1996, 382:716-719.
33. Heldmann U, Mine Y, Kokaia Z, Ekdahl CT, Lindvall O: Selective depletion
of Mac-1-expressing microglia in rat subventricular zone does not alter
neurogenic response early after stroke. Exp Neurol 2011, 229:391-398.
34. Montero M, Gonzalez B, Zimmer J: Immunotoxic depletion of microglia in
mouse hippocampal slice cultures enhances ischemia-like
neurodegeneration. Brain Res 2009, 1291:140-152.
35. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM,
Landreth GE: Microglia mediate the clearance of soluble Abeta through
fluid phase macropinocytosis. J Neurosci 2009, 29:4252-4262.
36. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G,
Kollias G, Cleveland DW: Onset and progression in inherited ALS
determined by motor neurons and microglia. Science 2006,
312:1389-1392.
37. Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R:
Activated microglia mediate axoglial disruption that contributes to
Minami et al. Journal of Neuroinflammation 2012, 9:22
http://www.jneuroinflammation.com/content/9/1/22
Page 12 of 13
axonal injury in multiple sclerosis. J Neuropathol Exp Neurol 2010,
69:1017-1033.
38. Tansey MG, Goldberg MS: Neuroinflammation in Parkinson’s disease: its
role in neuronal death and implications for therapeutic intervention.
Neurobiol Dis 2010, 37:510-518.
39. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D,
Kay DM, Doheny KF, Paschall J, Pugh E, et al: Common genetic variation in
the HLA region is associated with late-onset sporadic Parkinson’s
disease. Nat Genet 2010, 42:781-785.
40. Hardman R: A toxicologic review of quantum dots: toxicity depends on
physicochemical and environmental factors. Environ Health Perspect 2006,
114:165-172.
41. Zhang T, Stilwell JL, Gerion D, Ding L, Elboudwarej O, Cooke PA, Gray JW,
Alivisatos AP, Chen FF: Cellular effect of high doses of silica-coated
quantum dot profiled with high throughput gene expression analysis
and high content cellomics measurements. Nano Lett 2006, 6:800-808.
42. Clift MJ, Rothen-Rutishauser B, Brown DM, Duffin R, Donaldson K,
Proudfoot L, Guy K, Stone V: The impact of different nanoparticle surface
chemistry and size on uptake and toxicity in a murine macrophage cell
line. Toxicol Appl Pharmacol 2008, 232:418-427.
43. Clift MJ, Varet J, Hankin SM, Brownlee B, Davidson AM, Brandenberger C,
Rothen-Rutishauser B, Brown DM, Stone V: Quantum dot cytotoxicity in
vitro: An investigation into the cytotoxic effects of a series of different
surface chemistries and their core/shell materials. Nanotoxicology 2011,
5:664-74.
44. Seleverstov O, Phang JM, Zabirnyk O: Semiconductor nanocrystals in
autophagy research: methodology improvement at nanosized scale.
Methods Enzymol 2009, 452:277-296.
45. Seleverstov O, Zabirnyk O, Zscharnack M, Bulavina L, Nowicki M,
Heinrich JM, Yezhelyev M, Emmrich F, O’Regan R, Bader A: Quantum dots
for human mesenchymal stem cells labeling. A size-dependent
autophagy activation. Nano Lett 2006, 6:2826-2832.
46. Stern ST, Zolnik BS, McLeland CB, Clogston J, Zheng J, McNeil SE: Induction
of autophagy in porcine kidney cells by quantum dots: a common
cellular response to nanomaterials? Toxicol Sci 2008, 106:140-152.
47. Zabirnyk O, Yezhelyev M, Seleverstov O: Nanoparticles as a novel class of
autophagy activators. Autophagy 2007, 3:278-281.
48. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M,
Schneider MD, Levine B: Bcl-2 antiapoptotic proteins inhibit Beclin 1-
dependent autophagy. Cell 2005, 122:927-939.
doi:10.1186/1742-2094-9-22
Cite this article as: Minami et al.: Selective targeting of microglia by
quantum dots. Journal of Neuroinflammation 2012 9:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Minami et al. Journal of Neuroinflammation 2012, 9:22
http://www.jneuroinflammation.com/content/9/1/22
Page 13 of 13
